Vera Therapeutics, Inc.
VERANASDAQHealthcare● Active
$31.88
$-0.41(-1.27%)
Market Cap$2.3B
P/E Ratio—
52W High$56.05
52W Low$19.066
Vera Therapeutics, Inc. (VERA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VERA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.69
Est. -$1.33 · -27.2%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
VERA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$1.60 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.33 | -$1.69 | -27.2% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$1.34 | -$1.39 | -3.7% | — | — | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$1.20 | -$1.26 | -5.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.82 | -$1.20 | -46.3% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.75 | -$0.81 | -8.0% | — | — | — |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.83 | -$0.72 | +13.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.69 | -$0.85 | -23.2% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$1.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.69
EPS Est.
-$1.33
EPS Surpr.
-27.2%
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$1.39
EPS Est.
-$1.34
EPS Surpr.
-3.7%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$1.26
EPS Est.
-$1.20
EPS Surpr.
-5.0%
Revenue
—
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$1.20
EPS Est.
-$0.82
EPS Surpr.
-46.3%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.81
EPS Est.
-$0.75
EPS Surpr.
-8.0%
Revenue
—
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.72
EPS Est.
-$0.83
EPS Surpr.
+13.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.85
EPS Est.
-$0.69
EPS Surpr.
-23.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.30 | $-0.48 | $-0.03 | 1 |
| Q3 FY2027 | $-2.07 | $-0.76 | $-0.05 | 1 |
| Q2 FY2027 | $-2.60 | $-0.96 | $-0.07 | 1 |
| Q1 FY2027 | $-2.82 | $-1.04 | $-0.07 | 1 |
| Q4 FY2026 | $-3.54 | $-1.30 | $-0.09 | 1 |
| Q3 FY2026 | $-1.88 | $-1.52 | $-1.30 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.1B | $0.2B | 3 |
| Q3 FY2027 | $0.0B | $0.1B | $0.2B | 3 |
| Q2 FY2027 | $0.0B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.1B | 4 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -27.2% | $36.60 | $35.88 | -1.97% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -3.7% | $41.68 | $42.35 | +1.61% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -5.0% | $24.35 | $24.10 | -1.03% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -46.3% | $20.45 | $20.64 | +0.93% |
| ▼ Q2 FY2025 | May 6, 2025 | -8.0% | $25.53 | $22.01 | -13.79% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +13.3% | $27.10 | $27.77 | +2.47% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -23.2% | $47.94 | $49.04 | +2.29% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -6.9% | $35.65 | $35.85 | +0.56% |
Q2 FY2026-1.97%
Report Date
May 7, 2026
EPS Beat/Miss
-27.2%
Price Before
$36.60
Price After
$35.88
Q1 FY2026+1.61%
Report Date
Feb 26, 2026
EPS Beat/Miss
-3.7%
Price Before
$41.68
Price After
$42.35
Q4 FY2025-1.03%
Report Date
Nov 5, 2025
EPS Beat/Miss
-5.0%
Price Before
$24.35
Price After
$24.10
Q3 FY2025+0.93%
Report Date
Aug 5, 2025
EPS Beat/Miss
-46.3%
Price Before
$20.45
Price After
$20.64
Q2 FY2025-13.79%
Report Date
May 6, 2025
EPS Beat/Miss
-8.0%
Price Before
$25.53
Price After
$22.01
Q1 FY2025+2.47%
Report Date
Feb 26, 2025
EPS Beat/Miss
+13.3%
Price Before
$27.10
Price After
$27.77
Q4 FY2024+2.29%
Report Date
Nov 7, 2024
EPS Beat/Miss
-23.2%
Price Before
$47.94
Price After
$49.04
Q3 FY2024+0.56%
Report Date
Aug 8, 2024
EPS Beat/Miss
-6.9%
Price Before
$35.65
Price After
$35.85
Avg Beat Reaction+2.47%
Avg Miss Reaction-1.63%
Beat Rate1 / 8 quarters
Largest Move-13.79% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VERA ends December
Vera Therapeutics, Inc. (VERA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.69 — missing the analyst consensus of $-1.33 by -27.2%. The next VERA earnings date is expected around September 1, 2026.
Each quarter, investors track VERA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VERA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VERA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VERA earnings · 5 questionsVera Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. VERA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VERA historically reports after market close (AMC).
VERA earnings datewhen is VERA earningsVERA next earnings datewhen does VERA report earningsVERA earnings calendar
▸ Source: FMP · Vera Therapeutics, Inc. SEC filings · US GAAP · Vera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026